Miconazole Nitrate Oral Disintegrating Tablets: In Vivo Performance and Stability Study

被引:18
作者
Ahmed, Tarek A. [1 ,2 ]
El-Say, Khalid M. [1 ,2 ]
Mahmoud, Maged F. [2 ]
Samy, Ahmed M. [2 ]
Badawi, Alia A. [3 ]
机构
[1] King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Jeddah 21589, Saudi Arabia
[2] Al Azhar Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Cairo, Egypt
[3] Cairo Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Cairo, Egypt
来源
AAPS PHARMSCITECH | 2012年 / 13卷 / 03期
关键词
accelerated stability testing; bioavailability; foam granulation technique; miconazole nitrate; oral disintegrating tablet; CONTROLLED-RELEASE; DRUG; GRANULATION; COMPLEXES; DELIVERY; SYSTEM;
D O I
10.1208/s12249-012-9798-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The interest in and need for formulating miconazole nitrate (MN), a broad-spectrum antifungal, as an oral disintegrating tablet for treatment of some forms of candidiasis have increased. Formulation of MN in this dosage form will be more advantageous, producing dual effect:local in the buccal cavity and systemic with rapid absorption. Four formulations were prepared utilizing the foam granulation technique. The prepared tablets were characterized by measuring the weight uniformity, thickness, tensile strength, friability, and drug content. In addition, tablet disintegration time, in vitro dissolution, and in vivo disintegration time were also evaluated. Stability testing for the prepared tablets under stress and accelerated conditions in two different packs were investigated. Each pack was incubated at two different elevated temperature and relative humidity (RH), namely 40 +/- 2 degrees C/75 +/- 5% RH and 50 +/- 2 degrees C/75 +/- 5% RH. The purpose of the study is to monitor any degradation reactions which will help to predict the shelf life of the product under the defined storage conditions. Finally, in vivo study was performed on the most stable formula to determine its pharmacokinetic parameters. The results revealed that all the prepared tablets showed acceptable tablet characteristics and were stable under the tested conditions. The most stable formula was that containing magnesium stearate as lubricant, hydrophobic Aerosil R972 as glidant, low urea content, mannitol/microcrystalline cellulose ratio 2:1, and 9% Plasdone XL100 as superdisintegrant. The in vivo results revealed that the tested formula showed rapid absorption compared to the physical blend (t(max) were 1 and 4 h, respectively), while the extent of absorption was almost the same.
引用
收藏
页码:760 / 771
页数:12
相关论文
共 39 条
  • [1] [Anonymous], 1996, IMP NEW DRUG PROD
  • [2] [Anonymous], 2005, Int Conf Harmon, V1994, P17, DOI DOI 10.1201/9781482298468
  • [3] Aulton ME., 2002, PHARM SCI DOSAGE FOR, P154
  • [4] Barillaro V, 2004, J PHARM PHARM SCI, V7, P378
  • [5] Theoretical and experimental investigations on miconazole/cyclodextrin/acid complexes: Molecular modeling studies
    Barillaro, Valery
    Dive, Georges
    Bertholet, Pascal
    Evrard, Brigitte
    Delattre, Luc
    Eric, Ziemons
    Piel, Geraldine
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 342 (1-2) : 152 - 160
  • [6] COMPARISON OF SALIVARY MICONAZOLE CONCENTRATIONS AFTER ADMINISTRATION OF A BIOADHESIVE SLOW-RELEASE BUCCAL TABLET AND AN ORAL GEL
    BOUCKAERT, S
    SCHAUTTEET, H
    LEFEBVRE, RA
    REMON, JP
    VANCLOOSTER, R
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (02) : 137 - 140
  • [7] IN-VITRO BIOADHESION OF A BUCCAL, MICONAZOLE SLOW-RELEASE TABLET
    BOUCKAERT, S
    REMON, JP
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1993, 45 (06) : 504 - 507
  • [8] BURGESS DJ, 2004, AAPS PHARMSCI, V6
  • [9] EMEA The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products (CPMP), 1999, CPMPICH60496 EMEA, P1
  • [10] Faroongsarng Damrongsak, 2003, AAPS PharmSciTech, V4, pE67